Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.

Weiss R, Garg SK, Bergenstal RM, Klonoff DC, Bode BW, Bailey TS, Thrasher J, Schwartz F, Welsh JB, Kaufman FR; ASPIRE In-Home Study Group.

J Diabetes Sci Technol. 2015 May 18. pii: 1932296815586014. [Epub ahead of print]

PMID:
25986629
2.

Racial-ethnic disparities in management and outcomes among children with type 1 diabetes.

Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH; T1D Exchange Clinic Network.

Pediatrics. 2015 Mar;135(3):424-34. doi: 10.1542/peds.2014-1774.

PMID:
25687140
3.

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators.

J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.

PMID:
25670362
4.

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.

Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ; T1D Exchange Clinic Network.

Diabetes Care. 2015 Mar;38(3):476-81. doi: 10.2337/dc14-1952. Epub 2014 Dec 17.

PMID:
25519448
5.

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group.

Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-97. doi: 10.1016/S2213-8587(13)70214-6. Epub 2014 Feb 6. Erratum in: Lancet Diabetes Endocrinol. 2014 Mar;2(3):e5.

PMID:
24703047
6.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.

Arakaki RF, Blevins TC, Wise JK, Liljenquist DR, Jiang HH, Jacobson JG, Martin SA, Jackson JA.

Diabetes Obes Metab. 2014 Jun;16(6):510-8. doi: 10.1111/dom.12242. Epub 2013 Dec 29.

7.

A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience.

Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW, Cengiz E, Laffel LM, Miller KM, Haller MJ; T1D Exchange Clinic Network.

Pediatr Diabetes. 2014 Mar;15(2):110-7. doi: 10.1111/pedi.12067. Epub 2013 Aug 19.

8.

Threshold-based insulin-pump interruption for reduction of hypoglycemia.

Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR; ASPIRE In-Home Study Group.

N Engl J Med. 2013 Jul 18;369(3):224-32. doi: 10.1056/NEJMoa1303576. Epub 2013 Jun 22.

9.

A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system.

Christiansen M, Bailey T, Watkins E, Liljenquist D, Price D, Nakamura K, Boock R, Peyser T.

Diabetes Technol Ther. 2013 Oct;15(10):881-8. doi: 10.1089/dia.2013.0077. Epub 2013 Jun 18.

10.

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.

Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL, Bergenstal RM, Harris B, Dubose SN, Miller KM, Beck RW; T1D Exchange Clinic Network.

J Clin Endocrinol Metab. 2013 Aug;98(8):3411-9. doi: 10.1210/jc.2013-1589. Epub 2013 Jun 12.

PMID:
23760624
11.

Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines.

Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE; T1D Exchange Clinic Network.

Diabetes Care. 2013 Jul;36(7):2035-7. doi: 10.2337/dc12-1959. Epub 2013 Jan 22.

12.

The T1D Exchange clinic registry.

Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network.

J Clin Endocrinol Metab. 2012 Dec;97(12):4383-9. doi: 10.1210/jc.2012-1561. Epub 2012 Sep 20.

PMID:
22996145
13.

Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.

Rubin RR, Peyrot M; STAR 3 Study Group.

Diabetes Technol Ther. 2012 Feb;14(2):143-51. doi: 10.1089/dia.2011.0162. Epub 2011 Dec 1.

PMID:
22133037
14.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators.

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.

15.

Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators.

N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.

16.

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group.

N Engl J Med. 2010 Jul 22;363(4):311-20. doi: 10.1056/NEJMoa1002853. Epub 2010 Jun 29. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092.

17.

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators.

Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.

PMID:
19781408
18.

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.

Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group.

J Clin Endocrinol Metab. 2006 Jan;91(1):48-53. Epub 2005 Oct 25.

PMID:
16249284
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk